The Effect of Statins on Blood Gene Expression in COPD

Background COPD is currently the fourth leading cause of death worldwide. Statins are lipid lowering agents with documented cardiovascular benefits. Observational studies have shown that statins may have a beneficial role in COPD. The impact of statins on blood gene expression from COPD patients is largely unknown. Objective Identify blood gene signature associated with statin use in COPD patients, and the pathways underpinning this signature that could explain any potential benefits in COPD. Methods Whole blood gene expression was measured on 168 statin users and 451 non-users from the ECLIPSE study using the Affymetrix Human Gene 1.1 ST microarray chips. Factor Analysis for Robust Microarray Summarization (FARMS) was used to process the expression data. Differential gene expression analysis was undertaken using the Linear Models for Microarray data (Limma) package adjusting for propensity score and surrogate variables. Similarity of the expression signal with published gene expression profiles was performed in ProfileChaser. Results 25 genes were differentially expressed between statin users and non-users at an FDR of 10%, including LDLR, CXCR2, SC4MOL, FAM108A1, IFI35, FRYL, ABCG1, MYLIP, and DHCR24. The 25 genes were significantly enriched in cholesterol homeostasis and metabolism pathways. The resulting gene signature showed correlation with Huntington’s disease, Parkinson’s disease and acute myeloid leukemia gene signatures. Conclusion The blood gene signature of statins’ use in COPD patients was enriched in cholesterol homeostasis pathways. Further studies are needed to delineate the role of these pathways in lung biology.

[1]  N. Horita,et al.  Statins reduce all-cause mortality in chronic obstructive pulmonary disease: a systematic review and meta-analysis of observational studies , 2014, Respiratory Research.

[2]  J. Auwerx,et al.  A method to identify and validate mitochondrial modulators using mammalian cells and the worm C. elegans , 2014, Scientific Reports.

[3]  Meilan K. Han,et al.  Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. , 2014, The New England journal of medicine.

[4]  A. Zeki.  Simvastatin inhibits smoke-induced airway epithelial injury: implications for COPD therapy , 2014, European Respiratory Journal.

[5]  T. Steele,et al.  Statins inhibit proliferation and cytotoxicity of a human leukemic natural killer cell line , 2013, Biomarker Research.

[6]  Fuqiang Wen,et al.  Increased Serum ox-LDL Levels Correlated with Lung Function, Inflammation, and Oxidative Stress in COPD , 2013, Mediators of inflammation.

[7]  K. Gowdy,et al.  Emerging roles for cholesterol and lipoproteins in lung disease. , 2013, Pulmonary pharmacology & therapeutics.

[8]  M. Tobin,et al.  APOM and high-density lipoprotein cholesterol are associated with lung function and per cent emphysema , 2013, European Respiratory Journal.

[9]  Anil Kumar,et al.  Synergistical neuroprotection of rofecoxib and statins against malonic acid induced Huntington's disease like symptoms and related cognitive dysfunction in rats. , 2013, European journal of pharmacology.

[10]  Bin Chen,et al.  Relating genes to function: identifying enriched transcription factors using the ENCODE ChIP-Seq significance tool , 2013, Bioinform..

[11]  Jing Wang,et al.  WEB-based GEne SeT AnaLysis Toolkit (WebGestalt): update 2013 , 2013, Nucleic Acids Res..

[12]  J. Kastelein,et al.  Identification of a loss-of-function inducible degrader of the low-density lipoprotein receptor variant in individuals with low circulating low-density lipoprotein. , 2013, European heart journal.

[13]  M. Decramer,et al.  Chronic obstructive pulmonary disease and comorbidities. , 2013, The Lancet. Respiratory medicine.

[14]  K. Pinkerton,et al.  Simvastatin inhibits smoke-induced airway epithelial injury: implications for COPD therapy , 2012, European Respiratory Journal.

[15]  A. Zarbock,et al.  CXCR2: From Bench to Bedside , 2012, Front. Immun..

[16]  J. D’Armiento,et al.  Activation of the TLR4 signaling pathway and abnormal cholesterol efflux lead to emphysema in ApoE-deficient mice. , 2012, American journal of physiology. Lung cellular and molecular physiology.

[17]  K. Azzam,et al.  Crosstalk between reverse cholesterol transport and innate immunity , 2012, Trends in Endocrinology & Metabolism.

[18]  F. Bushman,et al.  Cxcr2 and Cxcl5 regulate the IL-17/G-CSF axis and neutrophil homeostasis in mice. , 2012, The Journal of clinical investigation.

[19]  Andrew E. Jaffe,et al.  Bioinformatics Applications Note Gene Expression the Sva Package for Removing Batch Effects and Other Unwanted Variation in High-throughput Experiments , 2022 .

[20]  J. Burgos,et al.  Simvastatin modulates the Alzheimer's disease-related gene seladin-1. , 2012, Journal of Alzheimer's disease : JAD.

[21]  Jesse M. Engreitz,et al.  ProfileChaser: searching microarray repositories based on genome-wide patterns of differential expression , 2011, Bioinform..

[22]  R. Kozlov,et al.  Serotypes of Streptococcus Pneumoniae in Children of Russian Federation , 2011, Pediatric Research.

[23]  D. Massaro,et al.  Developmental Alveologenesis: New Roles for ApoE and LDL Receptor , 2011, Pediatric Research.

[24]  Steven R. Jones,et al.  Advanced chronic obstructive pulmonary disease is associated with high levels of high-density lipoprotein cholesterol. , 2011, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[25]  P. Austin.  An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies , 2011, Multivariate behavioral research.

[26]  C. Culmsee,et al.  Statins — increasing or reducing the risk of Parkinson's disease? , 2011, Experimental Neurology.

[27]  K. Pahan,et al.  Prospects of Statins in Parkinson Disease , 2011, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[28]  J. Maurer.  Dynamic Hyperinflation During Daily Activities: Does COPD Global Initiative for Chronic Obstructive Lung Disease Stage Matter? , 2011 .

[29]  D. Sin,et al.  Statin reverses smoke-induced pulmonary hypertension and prevents emphysema but not airway remodeling. , 2011, American journal of respiratory and critical care medicine.

[30]  R. Curi,et al.  ABCA1 and ABCG1 expressions are regulated by statins and ezetimibe in Caco-2 cells , 2011, Drug metabolism and drug interactions.

[31]  G. Hoser,et al.  Different statins produce highly divergent changes in gene expression profiles of human hepatoma cells: a pilot study. , 2011, Acta biochimica Polonica.

[32]  Rafael A. Irizarry,et al.  A framework for oligonucleotide microarray preprocessing , 2010, Bioinform..

[33]  A. Remaley,et al.  ATP-binding cassette transporter G1 deficiency dysregulates host defense in the lung. , 2010, American journal of respiratory and critical care medicine.

[34]  D. Link,et al.  CXCR2 and CXCR4 antagonistically regulate neutrophil trafficking from murine bone marrow. , 2010, The Journal of clinical investigation.

[35]  A. Tall,et al.  Role of HDL, ABCA1, and ABCG1 transporters in cholesterol efflux and immune responses. , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[36]  R. Hopkins,et al.  Pharmacological actions of statins: potential utility in COPD , 2009, European Respiratory Review.

[37]  M. Etminan,et al.  Statins in COPD: a systematic review. , 2009, Chest.

[38]  G. Marks,et al.  Associations between statins and COPD: a systematic review , 2009, BMC pulmonary medicine.

[39]  P. Barter,et al.  Role of 3&bgr;-Hydroxysteroid-&Dgr;24 Reductase in Mediating Antiinflammatory Effects of High-Density Lipoproteins in Endothelial Cells , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[40]  F. V. Álvarez,et al.  Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE) , 2009 .

[41]  S. Hazen,et al.  Role of HDL , ABCA 1 , and ABCG 1 Transporters in Cholesterol Efflux and Immune Responses , 2009 .

[42]  V. Debari,et al.  Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD: evidence from a retrospective cohort study , 2008, International journal of clinical practice.

[43]  W. MacNee,et al.  Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE) , 2008, European Respiratory Journal.

[44]  C. Hedrick,et al.  A Critical Role for ABCG1 in Macrophage Inflammation and Lung Homeostasis1 , 2008, The Journal of Immunology.

[45]  P. Ping,et al.  Loss of ABCG1 Results in Chronic Pulmonary Inflammation1 , 2008, The Journal of Immunology.

[46]  P. Vokonas,et al.  Statin use reduces decline in lung function: VA Normative Aging Study. , 2007, American journal of respiratory and critical care medicine.

[47]  John D. Storey,et al.  Capturing Heterogeneity in Gene Expression Studies by Surrogate Variable Analysis , 2007, PLoS genetics.

[48]  B. Skipper,et al.  Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. , 2007, Chest.

[49]  J. Growdon,et al.  Molecular markers of early Parkinson's disease based on gene expression in blood , 2007, Proceedings of the National Academy of Sciences.

[50]  Robert Gentleman,et al.  Using GOstats to test gene lists for GO term association , 2007, Bioinform..

[51]  Andrew J. Brown,et al.  SREBP-2 positively regulates transcription of the cholesterol efflux gene, ABCA1, by generating oxysterol ligands for LXR. , 2006, The Biochemical journal.

[52]  Klaus Obermayer,et al.  A new summarization method for affymetrix probe level data , 2006, Bioinform..

[53]  W. Longmore,et al.  Regulation of lung surfactant cholesterol metabolism by serum lipoproteins , 1980, Lipids.

[54]  O. Francone,et al.  Pulmonary abnormalities due to ABCA1 deficiency in mice. , 2005, American journal of physiology. Lung cellular and molecular physiology.

[55]  R V Jensen,et al.  Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[56]  F. Mach,et al.  Statins Reduce Interleukin-6–Induced C-Reactive Protein in Human Hepatocytes: New Evidence for Direct Antiinflammatory Effects of Statins , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[57]  Gordon K Smyth,et al.  Statistical Applications in Genetics and Molecular Biology Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2011 .

[58]  Susumu Goto,et al.  The KEGG resource for deciphering the genome , 2004, Nucleic Acids Res..

[59]  R. Atmar,et al.  Biopsy neutrophilia, neutrophil chemokine and receptor gene expression in severe exacerbations of chronic obstructive pulmonary disease. , 2003, American journal of respiratory and critical care medicine.

[60]  Rafael A Irizarry,et al.  Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.

[61]  R. Perez,et al.  Ubiquinone does not rescue acute myeloid leukemia cells from growth inhibition by statins , 2003, Leukemia.

[62]  Y. Friedlander,et al.  Sterol-regulatory element-binding protein (SREBP)-2 contributes to polygenic hypercholesterolaemia. , 2002, Atherosclerosis.

[63]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[64]  W. Bailey,et al.  Editorial: Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 Guidelines for COPD, Including COVID-19, Climate Change, and Air Pollution , 2023, Medical science monitor : international medical journal of experimental and clinical research.

[65]  P. Cassano,et al.  Lipids and pulmonary function in the Third National Health and Nutrition Examination Survey. , 2002, American journal of epidemiology.

[66]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[67]  R. Evans,et al.  Nuclear receptors and lipid physiology: opening the X-files. , 2001, Science.

[68]  C. Stancu,et al.  Statins: mechanism of action and effects , 2001, Journal of cellular and molecular medicine.

[69]  R. Hohl,et al.  Interaction of cytosine arabinoside and lovastatin in human leukemia cells. , 2001, Leukemia research.

[70]  M. Ashburner,et al.  Gene Ontology: tool for the unification of biology , 2000, Nature Genetics.

[71]  Alan D. Lopez,et al.  Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study , 1997, The Lancet.

[72]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[73]  M. Simionescu,et al.  Uptake of low density lipoproteins by the hamster lung. Interactions with capillary endothelium. , 1986, The American review of respiratory disease.

[74]  S. Grundy,et al.  Increased high density lipoprotein cholesterol in obstructive pulmonary disease (predominant emphysematous type). , 1981, Metabolism: clinical and experimental.